Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Tecentriq® (atezolizumab) – Indication withdrawal
March 8, 2021 - Roche announced the voluntary withdrawal of the Tecentriq (atezolizumab) indication for patients with prior-platinum treated metastatic urothelial carcinoma (mUC).
